Skip to content
Catalyst Biosciences
Primary Menu
About
Overview
Management Team
Board of Directors
Strategic Partners
Pipeline
Overview
Hemostasis
Complement
Expanded Access Policy
Science
Overview
Publications
Clinical Trials
Overview
MAA-304
MAA-202
CB 4332
Investors
Press Releases
Events and Presentations
Events
Presentations
Scientific Presentations and Publications
Financials & Filings
Stock Information
Stock Quote
Stock Chart
Corporate Governance
Leadership Team
Board of Directors
Committee Composition
Investor FAQ
Careers
Career Opportunities
Benefits
Values
Contact
ISTH 2019 – Quality of Life of Hemophilia Patients with Inhibitors – Opportunities for Improvement
Post navigation
Previous:
CB 2782-PEG: a Complement Factor C3-Inactivating Protease and Potential Long-Acting Treatment for Dry AMD
Next:
ISTH 2019 – Phase 2/3 Trial of Subcutaneous Engineered FVIIa Marzeptacog Alfa (Activated) in Hemophilia A or B with Inhibitors: Efficacy, Safety and Pharmacokinetics
X
Previous
Next
